Experience low cost of ownership through a 93% first-pass yield and predictable reagent consumption.Hemasphere technology analyzes blood viscosity to optimize smearing, and next-generation DxH Slidemaker Stainer II ensures consistent slide qualityĮnsure predictable costs and >30% faster break-even point Facilitate confident slide interpretations through intelligent slide-making.Assess anemia with accuracy by maintaining near native-state cellular characterization throughout the RBC maturation cycle.The enhanced Coulter Principle provides a reportable MPV-even for thrombocytopenic patients-while DataFusion leverages inter-module intelligence to enable improved flagging and identification of interferences Support critical clinical decisions through advanced PLT analysis.These core technologies provide high-resolution characterization without altering cell morphology, providing excellent hematological test results Deliver reliable, reportable WBC differential results on the first run, through VCS 360 technology, DataFusion and the enhanced Coulter Principle.Achieve superb RBC, PLT and WBC differentials through near native-state cellular characterization
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |